![]() ![]() His work has a monolithic timeless quality. The beneficial effects of protease-activated receptor-1 antagonism on limb vascular events were accompanied by an increased risk of bleeding. Henry Timi I met Henry Timi this year at the Milan Design Fair while doing my annual assignment for Vogue Living. Vorapaxar did not reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with peripheral artery disease however, vorapaxar significantly reduced acute limb ischemia and peripheral revascularization. Perfect for small spaces, this bathroom collection features modular units that can fit together like a puzzle to create the perfectly optimized bathroom. Bleeding occurred more frequently with vorapaxar compared with placebo (7.4% versus 4.5% hazard ratio, 1.62 95% confidence interval, 1.21-2.18 P=0.001). However, rates of hospitalization for acute limb ischemia (2.3% versus 3.9% hazard ratio, 0.58 95% confidence interval, 0.39-0.86 P=0.006) and peripheral artery revascularization (18.4% versus 22.2% hazard ratio, 0.84 95% confidence interval, 0.73-0.97 P=0.017) were significantly lower in patients randomized to vorapaxar. In the peripheral artery disease cohort, the primary end point did not differ significantly with vorapaxar (11.3% versus 11.9% hazard ratio, 0.94 95% confidence interval, 0.78-1.14 P=0.53). The primary efficacy end point was cardiovascular death, myocardial infarction, or stroke, and the principal safety end point was Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) bleeding. Patients with qualifying peripheral artery disease (n=3787) had a history of claudication and an ankle-brachial index of <0.85 or prior revascularization for limb ischemia. The Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA2°P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with stable atherosclerotic vascular disease (myocardial infarction, stroke, or peripheral artery disease). The makers first piece to be offered at auction was 'A Moebius Collection HTFD302 Table' at Theodore Bruce, New South Wales in 2019. Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization. SHOWCASING A QUIET AND POETIC VISION, MELBOURNE-BASED PHOTOGRAPHER. In this philosophical conversation, Henry Timi shares insight on his love of travertine, his most significant commission to date, and his constant quest for aesthetic perfection, the essence in absence, the symbolic and the eternal.Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for thrombin on human platelets that is also present on vascular endothelium and smooth muscle. ![]() It’s here he also researches, experiments and percolates ideas for new projects.įollowing our exclusive tour through Henry Timi’s Milan Apartment in est Magazine issue #33, we jumped at the opportunity to speak with the designer and artist. All designs by HENRYTIMI, including the monolithic HTGR60 Kitchen and HTGR702 Basin are handcrafted in his factory in Italy. Henry Timi’s designs are lauded for their Italian craftsmanship, as he credits the history of Italian cities as a principal source of inspiration. ![]() ![]() The importance of nature is embedded in everything Henry Timi touches – especially in his own home. He works exclusively with natural materials and most pertinently timber and stone, enjoying the privilege of transforming these materials with his hands. Every design that leaves Henry Timi’s namesake studio HENRYTIMI embodies a resolute vision: quiet in nature, simplistic yet luxurious, monastic and restrained. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |